Beyond Aspirin, Clopidogrel Rising: A New Era 💊➡️🧬🚀
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI.
Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference.
The implication is subtle but profound: we may be witnessing the quiet reshaping of antiplatelet strategy.
In cardiology, tradition often lingers—but data, eventually, prevails.